Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

We report a phase I pharmacological study of an oral formulation of CKD‐516, a vascular‐disrupting agent, in patients with refractory solid tumors. Twenty‐seven patients (16 in the dose‐escalation cohort and 11 in the expansion cohort) received a single daily dose (5‐25 mg) of CKD‐516 five days per...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacol Res Perspect
Main Authors: Kim, Hark Kyun, Kang, Jeong Won, Park, Young‐Whan, Kim, Jung Young, Kim, Minchae, Kim, Soo Jin, Kim, Se‐mi, Ho Ryu, Keun, Yoon, Seonghae, Kim, Yun, Cho, Joo‐Youn, Lee, Keun Seok, Yun, Tak, Kim, Kiwon, Kwak, Mi Hyang, Kim, Tae‐Sung, Chung, Jinsoo, Park, Joong‐Won
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066534/
https://ncbi.nlm.nih.gov/pubmed/32162844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.568
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares